How should viability of Borrelia burgdorferi be demonstrated?
Nadelman
R B
RB
Nowakowski
J
J
Wormser
G P
GP
Schwartz
I
I
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015748:Borrelia burgdorferi Group / Q000235:genetics / Q000302:isolation & purification*; D004269:DNA, Bacterial / Q000302:isolation & purification; D005356:Fibromyalgia / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008193:Lyme Disease / Q000150:complications* / Q000188:drug therapy; D018482:Muscle, Skeletal / Q000382:microbiology*; D016133:Polymerase Chain Reaction
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial